Varenicline solution (nasal spray)
Treatment for Dry Eye Disease
Typical Dosage: One spray in each nostril twice daily
Effectiveness
78%
Safety Score
75%
Clinical Trials
4
Participants
1.8K
Comparative Safety Scale(Higher is safer)
Cyanideâ ī¸
Methđ
CigarettesđŦ
Chemoâĸī¸
Alcoholđē
Morphineđ
Antibioticsđ
Tylenolđ
Exerciseđ
Waterđ§
75
DangerousModerateSafe
Treatment Details
Dosage Range
One spray in each nostril twice daily
Time to Effect
Within days to 2 weeks
Treatment Duration
lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$9,000
Monitoring:$600
Side Effect Mgmt:$50
Total Annual:$9,650
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$11,000/QALY
QALYs Gained
0.06
Outcome-Based Costs
Cost per Responder
$17,545
Cost per Remission
$64,333
Comparison vs Artificial Tears
Cost Difference
+$9,050/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$6,570
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$90/year
Travel + wait time
Insurance Admin Cost
$80/year
Prior auth, claims
Rx Price
$9,000/year
Potential OTC Price
$800/year
Estimated if OTC available
Early Treatment Benefit
+0.02 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWVarenicline solution (nasal spray) Outcomes
for Dry Eye Disease
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+55%
Remission Rate
+15%
Common Side Effects
Sneezing
+82%
Cough
+16%
Throat irritation
+13%
Active Clinical Trials
2 active trials recruiting for Varenicline solution (nasal spray) in Dry Eye Disease
Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg
NCT07705893RECRUITINGNA
50 participants
INTERVENTIONAL
Houston, United States
Started: Jul 28, 2026
Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment
NCT07606625RECRUITINGPHASE4
65 participants
INTERVENTIONAL
Berkeley, United States
Started: Mar 6, 2026
Completed Clinical Trials
4 completed trials for Varenicline solution (nasal spray) in Dry Eye Disease
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease
NCT05576415COMPLETEDPHASE1
9 participants
INTERVENTIONAL
Shanghai, China
Started: Dec 7, 2022
Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease
NCT05378945COMPLETEDPHASE3
340 participants
INTERVENTIONAL
Hefei, China +19 more
Started: Jul 22, 2022
Nasal Spray Study in Sjogren's Dry Eye Disease
NCT05700422COMPLETEDPHASE4
39 participants
INTERVENTIONAL
Philadelphia, United States
Started: May 1, 2023
Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray
NCT05514041COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Venice, United States
Started: Oct 11, 2022